The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Meanwhile, Novo has been busy forging deals with telehealth platforms, like Hims & Hers (HIMS), to increase access to Wegovy. Novo also scored an exclusive deal to be listed as the preferred ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...